Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

Bone Marrow Transplantation

Volumn 46, Issue 7, 2011, Pages 1000-1005

  Castagna, L ^a   Furst S ^a   Marchetti, N ^b   El Cheikh, J ^a   Faucher, C ^a   Mohty, M ^c   Bouabdallah, R ^a   Vey, N ^a   Stoppa, A M ^a   Esterni, B ^a   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b HOSPITAL MACIEL   (Uruguay)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

allogeneic; elderly; RIC

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER THERAPY; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ELDERLY CARE; EUROPEAN BMT SCORE; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PREDICTION; PRETRANSPLANTATION ASSESSMENT OF MORTALITY SCORE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; WHOLE BODY RADIATION;

AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79960174811     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.227     Document Type: Article

References (19)

1. Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007; 92: 533-541. (Pubitemid 350147795)
2. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-1887.
3. Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005; 11: 764-772. (Pubitemid 41403758)
4. Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007; 82: 863-866. (Pubitemid 47502692)
5. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480-1484. (Pubitemid 46594099)
6. Spyridonidis A, Bertz H, Ihorst G, Grüllich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (4 or 60 years) with active myeloid malignancies. Blood 2005; 105: 4147-4148. (Pubitemid 40656169)
7. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, et al. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant 2004; 34: 155-159. (Pubitemid 39077107)
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
9. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
10. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, et al. Hematopoietic cell transplantationcomorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992-2001. (Pubitemid 351574075)
11. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009; 23: 1131-1138.
12. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 2: 223-230.
13. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407-414. (Pubitemid 46768162)
14. Gratwohl A, Stern M, Brand R. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726.
15. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476. (Pubitemid 36841962)
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reducedintensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395-1400. (Pubitemid 46239569)
18. Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22: 2062-2069.
19. Guilfoyle R, Demers A, Bredeson C, Richardson E, RubingerM, Szwajcer D, et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133-139.